CBD & nutraceutical merchant accounts.
Compliant card processing for CBD, hemp and supplement brands. Approval for products banks misclassify, with subscription tooling and acquirers that understand the category.
Why CBD & nutra is considered high-risk.
Acquiring banks label this vertical high-risk for a few specific reasons, then decline good businesses by default. Understanding why is the first step to getting approved.
- Regulatory ambiguity: hemp-derived CBD is legal in many markets but frequently misclassified by acquirers.
- Chargeback exposure: free-trial and subscription models attract disputes and friendly fraud.
- Claims risk: health and ingredient claims invite regulatory and reputational scrutiny.
Banks lump CBD in with cannabis
Legal hemp-derived CBD is wrongly declined alongside controlled substances.
Subscription & continuity disputes
Recurring nutra billing draws higher chargebacks and scrutiny.
Shifting compliance rules
Labelling, THC limits and claims rules change by market.
Approval, routing and risk tooling for CBD.
Specialist approval
We underwrite CBD businesses and present your application to acquirers that actively support the vertical.
Intelligent routing
Spread volume and cascade declines across acquirers for higher acceptance and resilience.
Chargeback tooling
Alerts, representment and prevention integrations to keep your ratios in policy.
Global acquiring
EU, UK and offshore acquiring with multi-currency settlement from one integration.
